Form 4: Bicara Therapeutics COO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics President and COO Ryan Cohlhepp sold 149 shares of common stock for $18.02 per share under a pre-arranged trading plan.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), reported a sale of common stock.
• The transaction involved the disposition of 149 shares of Bicara Therapeutics common stock.
• The shares were sold at a price of $18.02 per share.
• The sale occurred on January 15, 2026.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on February 12, 2025.
• Following this transaction, Ryan Cohlhepp directly beneficially owns 213,992 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of market sentiment as it does not necessarily reflect new information about the company's performance or outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by an insider under a 10b5-1 plan is unlikely to have a significant impact on existing shareholders.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Insider Trading, Stock Sale, Ryan Cohlhepp, 10b5-1 Plan, Form 4